We are live on ! Find out more
AIIC

AJU IB Investment Company Portfolio holdings

AUM $30.5M
1-Year Est. Return 128.96%
This Fund
S&P 500
This Quarter Est. Return
-9.1%
1 Year Est. Return
+128.96%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$103M
AUM Growth
Cap. Flow
+$116M
Cap. Flow %
112.56%
Top 10 Hldgs %
100%
Holding
8
New
8
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$90.5M
2
KYMR icon
Kymera Therapeutics
KYMR
+$20.6M
3
SEER icon
Seer Inc
SEER
+$1.79M
4
RLYB icon
Rallybio
RLYB
+$790K
5
XLO icon
Xilio Therapeutics
XLO
+$656K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$80.3M 78.19%
+1,047,557
New +$90.5M
KYMR icon
2
Kymera Therapeutics
KYMR
$8.94B
$18.4M 17.89%
+457,059
New +$20.6M
SEER icon
3
Seer Inc
SEER
$120M
$1.89M 1.84%
+816,375
New +$1.79M
RLYB icon
4
Rallybio
RLYB
$85.8M
$724K 0.71%
+94,335
New +$790K
XLO icon
5
Xilio Therapeutics
XLO
$60.3M
$638K 0.62%
+47,696
New +$656K
STRO icon
6
Sutro Biopharma
STRO
$421M
$322K 0.31%
+17,500
New +$534K
CARM
7
DELISTED
Carisma Therapeutics
CARM
$301K 0.29%
+718,332
New +$592K
RAPT
8
DELISTED
RAPT Therapeutics
RAPT
$157K 0.15%
+12,438
New +$158K

Similar funds

AJU IB Investment Company's Q4 2024 Portfolio in Review

Q4 2024 is the first quarter with a 13F filing on record for AJU IB Investment Company, which disclosed 8 positions worth $103M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Arcellx: 1,047,557 shares worth $80.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • AJU IB Investment Company's largest Q4 2024 buy was Arcellx: 1,047,557 shares worth $80.3M.
  • AJU IB Investment Company's ten largest holdings make up 100% of its $103M portfolio in Q4 2024.
  • AJU IB Investment Company disclosed 8 positions in Q4 2024, its first 13F filing on record.

Based on AJU IB Investment Company's 13F filing for Q4 2024, filed 8 Apr 2025.